Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 7 Rectal Neoplasms 3 Colorectal Neoplasms 3 Stomach Neoplasms 2 Neoplasm, Residual 2 Mesothelioma, Malignant 2 Colonic Neoplasms 2 Uterine Cervical Neoplasms 1 Solitary Fibrous Tumor, Pleural 1 Sarcopenia 1 Sarcoglycanopathies 1 Peritoneal Neoplasms 1 Pancreatic Neuroendocrine Tumors (pNET) 1 Pancreatic Neoplasms 1 Nasopharyngeal Carcinoma 1 NSCLC 1 Mesothelioma 1 Melanoma 1 Malnutrition 1 Lung Neoplasms 1 HER2 Negative Breast Cancer 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Frailty 1 Esophageal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1

Interventions

Radiotherapy 4 osimertinib 3 aflutinib 3 Radiosurgery 3 Pemetrexed 3 Drug Therapy 3 Carboplatin 3 toripalimab 2 pembrolizumab 2 Docetaxel 2 tislelizumab 1 sugemalimab 1 lenvatinib 1 cemiplimab 1 brigatinib 1 Vinorelbine 1 Tyrosine Kinase Inhibitors 1 Surgical Procedures, Operative 1 S 1 (combination) 1 Platinum Compounds 1 Platinum 1 Pharmaceutical Preparations 1 Paclitaxel 1 Neoadjuvant Therapy 1 JDQ443 1 Immune Checkpoint Inhibitors 1 HM781-36B 1 Gemcitabine 1 Diphenhydramine 1 Cryotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NSCLC × Chemotherapy, Adjuvant × 1 year × Clear all

NCT07089199 2025-07-28

TitAN

Qilu Hospital of Shandong University

Phase 2 Not yet recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡